Login or Register to unlock everything MedSchool has to offer!


The information in this section has been adapted in part from the Australian Therapeutic Goods Association website's repository of product information documents, which are available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI.
 Abrahamsen B. Adverse Effects of Bisphosphonates. Calcif Tissue Int. 2010; 86: 421-435. Abulayha A, Bredan A, El Enshasy H, Daniels I. Rituxumab: modes of action, remaining dispute and future perspective. Future Oncology. 10(15): 2481-2492. Adami S, Zamberlan N. Adverse Effects of Bisphosphonates: A Comparative Review. Drug Safety. 1996; 14(3): 156-170. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anti-Cancer Drugs. 2002;13 Suppl 2:S3-S10. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug.Seminars in Arthritis and Rheumatism. 1993;23:82-91. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. The Journal of Immunology. 1996; 156(5): 1937-1941. Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Seminars in arthritis and rheumatism. 2015;45:341-350. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008; 10(3): 218-227. Pacher P, Nivorozhkin A, Szabo C. Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol. Pharmacological reviews. 2006; 58(1): 87-114. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996 Jun; 97(12): 2692–2696. Wallace S. Mechanism of action of colchicine. Arthritis & Rheumatism. 1965; 8(4): 744–748. Weiner LM, Surana R, Wang S. Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy. Nature Reviews Immunology. 2010 May; 10: 317-327.